Evidence map›Paper›PMID 27556297›Full record

ArticleOncotarget2016

Deregulated FADD expression and phosphorylation in T-cell lymphoblastic lymphoma.

José L Marín-Rubio, María C de Arriba, María A Cobos-Fernández, Laura González-Sánchez, Inmaculada Ors, Isabel Sastre, José Fernández-Piqueras, María Villa-Morales

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. A Dual Role for FADD in Human Precursor T-Cell Neoplasms.International journal of molecular sciences · 2022
    Article
  4. FADD as a key molecular player in cancer progression.Molecular medicine (Cambridge, Mass.) · 2022
    Review
  5. A Review of DUSP26: Structure, Regulation and Relevance in Human Disease.International journal of molecular sciences · 2021
    Review
  6. Article
  7. Article
  8. Cancers · 2019
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

José L Marín-RubioCentro de Biología Molecular Severo Ochoa (CBMSO), Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.
María C de ArribaUniversidad Carlos III, Departamento de Bioingeniería, Madrid, Spain.
María A Cobos-FernándezCentro de Biología Molecular Severo Ochoa (CBMSO), Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.
Laura González-SánchezCentro de Biología Molecular Severo Ochoa (CBMSO), Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.
Inmaculada OrsUniversidad Autónoma de Madrid, Departamento de Biología, Madrid, Spain.
Isabel SastreCentro de Biología Molecular Severo Ochoa (CBMSO), Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.
José Fernández-PiquerasCentro de Biología Molecular Severo Ochoa (CBMSO), Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.
María Villa-MoralesCentro de Biología Molecular Severo Ochoa (CBMSO), Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.
Universidad Autónoma de Madrid · ESHospital Universitario Fundación Jiménez Díaz · ESCentre for Biomedical Network Research on Rare Diseases · ESCentro de Investigación Biomédica en Red · ESCentro de Investigaciones Energéticas, Medioambientales y Tecnológicas · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the present work, we show that T-cell lymphoblastic lymphoma cells exhibit a reduction of FADD availability in the cytoplasm, which may contribute to impaired apoptosis. In addition, we observe a reduction of FADD phosphorylation that inversely correlates with the proliferation capacity and tumor aggressiveness. The resultant balance between FADD-dependent apoptotic and non-apoptotic abilities may define the outcome of the tumor. Thus, we propose that FADD expression and phosphorylation can be reliable biomarkers with prognostic value for T-LBL stratification.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsApoptosisBiomarkers, TumorCasein Kinase IalphaCell ProliferationCytoplasmDNA, ComplementaryDown-RegulationDual-Specificity PhosphatasesFas-Associated Death Domain ProteinFemaleGene Expression ProfilingHumansImmunohistochemistryIntracellular Signaling Peptides and ProteinsBiomarkers, TumorCasein Kinase IalphaDNA, ComplementaryDual-Specificity PhosphatasesDUSP26 protein, humanFADD protein, humanFas-Associated Death Domain ProteinHIPK3 protein, humanIntracellular Signaling Peptides and ProteinsMitogen-Activated Protein Kinase PhosphatasesProtein Serine-Threonine KinasesSerineexpression and phosphorylationFas-associated death domain protein (FADD)prognostic markerT-cell lymphoblastic lymphomatumor aggressiveness

Identifiers

PMID27556297
PMCPMC5308666
OpenAlexW2518104172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.